Can Vir Biotechnology (VIR)'s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? [Yahoo! Finance]
Vir Biotechnology, Inc. (VIR)
Company Research
Source: Yahoo! Finance
that it had dosed the first patient in one of three dose-expansion cohorts in its ongoing Phase 1 trial of VIR-5500. VIR-5500 is an investigational treatment for metastatic prostate cancer. Can Vir Biotechnology (VIR)'s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? Pressmaster/Shutterstock.com VIR-5500 is a type of therapy that redirects the immune system's T-cells to attack cancer cells expressing the prostate-specific membrane antigen (PSMA). It leverages Vir's proprietary PRO-XTEN dual-masked T-cell engager (TCE) technology. The “masking” component of the technology is designed to reduce the risk of cytokine release syndrome (CRS), which is a dangerous immune overreaction that typically limits how aggressively T-cell engagers can be dosed, according to Vir. The company said the expansion cohort is now enrolling targets patients with late-line metastatic castration-resistant prostate cancer, or mCRPC. These are male patients whose disease has progresse
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In? [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate CancerBusiness Wire
- Vir Biotechnology (VIR) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate CancerBusiness Wire
VIR
Earnings
- 2/23/26 - Beat
VIR
Sec Filings
- 4/16/26 - Form ARS
- 4/16/26 - Form DEFA14A
- 4/16/26 - Form DEF
- VIR's page on the SEC website